6234 RESULTS
CONFERENCE COVERAGE 2024-08-30 Conference Coverage As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association International Conference, held last month
CONFERENCE COVERAGE 2024-08-29 Conference Coverage Now that lecanemab has been in clinical use in the U.S. for a little over a year, doctors are asking how long they should treat. This remains an open question. Drug maker Eisai has proposed to the FDA, in a supplemental biological lice
CONFERENCE COVERAGE 2024-08-28 Conference Coverage The brain shrinkage seen on amyloid immunotherapy remains an unsolved and concerning riddle. At the Alzheimer’s Association International Conference, held July 27 to August 1 in Philadelphia, Nick Fox of University College London offer
CONFERENCE COVERAGE 2024-08-27 Conference Coverage In the brain, location is everything. And the throngs of cells that live there are nothing without the billions of distinct connections between them. Although scientists can use single-cell transcriptomics to survey gene expression in
CONFERENCE COVERAGE 2024-08-23 Conference Coverage A new multiplex diagnostic method appears poised to resculpt the biomarker landscape. NULISA, aka NUcleic acid Linked Immunosorbent Assay, can detect Aβ peptides, p-tau isoforms, and other potential markers of neurodegeneration with se
CONFERENCE COVERAGE 2024-08-23 Conference Coverage Jab a finger, draw up a spot of blood with a test strip, let it dry, then mail it off to your doctor. Could testing for Alzheimer’s disease become that simple? Quite possibly. Modern immunoassays are so sensitive they can detect marker
CONFERENCE COVERAGE 2024-08-22 Conference Coverage With many different blood markers and assays for helping doctors diagnose Alzheimer’s disease, which are they to choose? Head-to-head studies can help answer this question, but few have directly compared blood tests on the same samples
CONFERENCE COVERAGE 2024-08-22 Conference Coverage Mass spectrometry tests, immunoassays, Aβ42/40, various p-taus, their ratios … the number of blood tests for amyloid pathology in the last seven years has blossomed into a hopeful but confusing mess. Some are CLIA-certified—meaning the
CONFERENCE COVERAGE 2024-08-22 Conference Coverage Clinicians may soon have a blood test for neurofibrillary tangles. At AAIC 2024, held July 27-31 in Philadelphia, Randall Bateman, Washington University, St. Louis, reported that a fragment of tau containing the microtubule-binding reg
CONFERENCE COVERAGE 2024-08-16 Conference Coverage At the AAIC conference held 27 July to 1 August in Philadelphia, microglial epigenetics stood in the limelight. Microglia are infamous for their dynamic and varied responses to different threats they encounter within the brain environs
CONFERENCE COVERAGE 2024-08-16 Conference Coverage When confronting a threat, microglia rapidly splinter off into a menagerie of transcriptional states. What purpose do they serve? And who’s in charge of orchestrating them? These are difficult questions for scientists trying to underst
CONFERENCE COVERAGE 2024-08-16 Conference Coverage As more people are treated with lecanemab and donanemab in clinical care, the risk of serious reactions due to ARIA grows. At AAIC, held July 28 to August 1 in Philadelphia, clinicians discussed how to avoid those by screening patients
CONFERENCE COVERAGE 2024-08-16 Conference Coverage With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug Administration, and gained insuranc
CONFERENCE COVERAGE 2024-08-16 Conference Coverage The γ-secretase enzyme complex—abandoned as a drug target after candidate molecules proved toxic—is getting another look. New research has correlated the degree to which presenilin mutations affect the enzyme’s propensity to churn out
CONFERENCE COVERAGE 2024-08-09 Conference Coverage Among the hundreds of studies presented at this year’s Alzheimer’s Association International Conference, held July 27 to August 1 in Philadelphia, one of the few that made a splash in the news was not news at all. Perhaps spurred by a
